Suvrat Bhargave
Tyrone, GANPI 1720070501
Payments from drug & device makers
$1,072,583in general payments, 2019–2025
Across 2,033 payments — averaging $527.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$610K
- Corium, LLC$230K
- Tris Pharma Inc$77K
- Axsome Therapeutics, Inc.$71K
- Supernus Pharmaceuticals, Inc.$39K
- Noven Pharmaceuticals, Inc.$27K
- plus $18K from 20 others
General payments by program year
19
20
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 1,084 | $610,383 |
| Corium, LLC | 362 | $229,590 |
| Tris Pharma Inc | 177 | $76,611 |
| Axsome Therapeutics, Inc. | 99 | $71,394 |
| Supernus Pharmaceuticals, Inc. | 92 | $39,315 |
| Noven Pharmaceuticals, Inc. | 22 | $26,856 |
| Ironshore Pharmaceuticals Inc. | 52 | $10,063 |
| Adlon Therapeutics L.p. | 10 | $4,969 |
| Noven Therapeutics, LLC | 9 | $1,000 |
| Neos Therapeutics, LP | 21 | $412 |
| Otsuka America Pharmaceutical, Inc. | 19 | $373 |
| Teva Pharmaceuticals USA, Inc. | 16 | $299 |
| Alkermes, Inc. | 13 | $261 |
| Alfasigma USA, Inc. | 8 | $152 |
| Vertical Pharmaceuticals, LLC | 9 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $136 |
| Neurocrine Biosciences, Inc. | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| Shire North American Group Inc | 4 | $73 |
| Collegium Pharmaceutical, Inc. | 3 | $60 |
| Johnson & Johnson | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $56 |
| Lundbeck LLC | 2 | $44 |
| Bausch Health US, LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.